Effector memory CD8 T-cells as a novel peripheral blood biomarker for activated T-cell pediatric acute liver failure.
Effector memory CD8 T-cells as a novel peripheral blood biomarker for activated T-cell pediatric acute liver failure.
复制标题
DOI:
10.1371/journal.pone.0286394
复制
发表时间:
2023
期刊:
影响因子:
3.7
通讯作者:
中科院分区:
文献类型:
--
作者:
A distinct phenotype of pediatric acute liver failure (PALF) has been identified, labeled activated T-cell hepatitis. These patients, previously included within the indeterminate group, have evidence of systemic immune activation and liver biopsy specimens with dense infiltration of CD8+ T-cells. We aimed to evaluate the peripheral blood T-cell phenotype in PALF patients with activated T-cell hepatitis compared to indeterminate cause. PALF patients with unknown etiology age 1–17 years were prospectively enrolled between 2017–2020. Within the unknown group, patients were classified as either activated T-cell hepatitis if they had a liver biopsy with dense or moderate CD8 staining and an elevated soluble interleukin-2 receptor level, or they were classified as indeterminate if they did not meet these criteria. Whole blood was collected for flow cytometry and T-cell phenotyping. Four patients with activated T-cell hepatitis and 4 patients with indeterminate PALF were enrolled. Activated T-cell hepatitis patients had significantly greater percentage of CD8 T-cells that were effector memory (TEM) phenotype compared to indeterminate PALF patients (median 66.8% (IQR 57.4–68.7) vs 19.1% (IQR 13.4–25.2), P = 0.03). In addition, CD8+ TEM cells in activated T-cell hepatitis patients were significantly more likely to be CD103 positive, a marker of tissue resident memory T-cells, compared to indeterminate PALF patients (median 12.4% (IQR 9.5–14.7) vs 4.7% (IQR 4.5–5.3), P = 0.03). We found patients with activated T-cell hepatitis can be identified by the unique pattern of increased percentage of peripheral blood effector memory CD8+ CD103+ T-cells. These findings will guide future studies exploring the T-cell phenotype for these patients and whether they may respond to directed immunosuppressive therapies.
登录
查看更多内容
影响因子:
1
作者:
Boeske, Anne-Kathrin;Sander, Annette;Pfister, Eva-Doreen
通讯作者:
Pfister, Eva-Doreen
影响因子:
13.5
作者:
Chapin, Catherine A.;Burn, Thomas;Alonso, Estella M.
通讯作者:
Alonso, Estella M.
影响因子:
1.3
作者:
McKenzie, Rebecca B.;Berquist, William E.;Cox, Kenneth L.
通讯作者:
Cox, Kenneth L.
影响因子:
8.8
作者:
Molina, RA;Katzir, L;Martín, MG
通讯作者:
Martín, MG
DOI:
10.1097/mpg.0b013e31827a78b2
发表时间:
2013-03
影响因子:
2.9
作者:
Bucuvalas J;Filipovich L;Yazigi N;Narkewicz MR;Ng V;Belle SH;Zhang S;Squires RH
通讯作者:
Squires RH